MA33402B1 - Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps - Google Patents

Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps

Info

Publication number
MA33402B1
MA33402B1 MA34415A MA34415A MA33402B1 MA 33402 B1 MA33402 B1 MA 33402B1 MA 34415 A MA34415 A MA 34415A MA 34415 A MA34415 A MA 34415A MA 33402 B1 MA33402 B1 MA 33402B1
Authority
MA
Morocco
Prior art keywords
methods
targeting
antibody
formulations
complementary
Prior art date
Application number
MA34415A
Other languages
Arabic (ar)
English (en)
Inventor
Bijan Etemad-Gilbertson
Braydon Charles Guild
Yong-In Kim
Ingo Klagge
Alexandra Kraus
Michael Roguska
Igor Splawski
Kehao Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33402B1 publication Critical patent/MA33402B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps et leurs fragments de liaison aux antigènes qui se lient à la fois à la protéine C3b du complément humain et à la protéine C3b du complément cynomolgus, ainsi que des compositions et des procédés d'utilisation associés.
MA34415A 2009-05-06 2010-05-05 Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps MA33402B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17586009P 2009-05-06 2009-05-06
PCT/EP2010/056129 WO2010136311A2 (fr) 2009-05-06 2010-05-05 Compositions et procédés de ciblage de la protéine c3b de complément par des anticorps

Publications (1)

Publication Number Publication Date
MA33402B1 true MA33402B1 (fr) 2012-07-03

Family

ID=43063291

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34415A MA33402B1 (fr) 2009-05-06 2010-05-05 Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps

Country Status (22)

Country Link
US (1) US20100291106A1 (fr)
EP (1) EP2427491A2 (fr)
JP (1) JP2012525829A (fr)
KR (1) KR20120088551A (fr)
CN (1) CN102459334A (fr)
AR (1) AR076655A1 (fr)
AU (1) AU2010252156A1 (fr)
CA (1) CA2760757A1 (fr)
CL (1) CL2011002756A1 (fr)
CO (1) CO6440515A2 (fr)
EA (1) EA201101593A1 (fr)
EC (1) ECSP11011445A (fr)
IL (1) IL216061A0 (fr)
MA (1) MA33402B1 (fr)
MX (1) MX2011011754A (fr)
PE (1) PE20120899A1 (fr)
SG (1) SG175432A1 (fr)
TN (1) TN2011000528A1 (fr)
TW (1) TW201043638A (fr)
UY (1) UY32612A (fr)
WO (1) WO2010136311A2 (fr)
ZA (1) ZA201107551B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107708A1 (fr) 2004-04-30 2005-11-17 Allergan, Inc. Implants d'inhibiteurs de tyrosine kinase intravitreens, biodegradables
US7759304B2 (en) 2006-06-21 2010-07-20 Regents Of The University Of Colorado Targeting complement factor H for treatment of diseases
WO2011003098A1 (fr) 2009-07-02 2011-01-06 Musc Foundation For Research Development Procédés de stimulation de la régénération du foie
CA2795311A1 (fr) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Traitement de l'hemoglobinurie paroxystique nocturne, des anemies hemolytiques et des etats pathologiques impliquant l'hemolyse intravasculaire et extra-vasculaire
BR112012029067A2 (pt) 2010-05-14 2019-09-24 Univ Colorado Regents grupos-alvo de receptor do complemento 2 (cr2) melhorados.
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
US8940490B2 (en) * 2010-11-29 2015-01-27 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
CA2869477C (fr) * 2012-04-03 2020-06-09 Novelmed Therapeutics, Inc. Anticorps anti-facteur c3 humanises et chimeriques, et leurs utilisations
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
EP3722320A3 (fr) 2012-10-25 2020-12-30 Bioverativ USA Inc. Anticorps c1s anti-complément et leurs utilisations
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
MX2015006738A (es) * 2012-11-29 2015-08-05 Bayer Healthcare Llc Anticuerpos monoclonales humanizados contra la proteina c activada y sus usos.
EP2978451B1 (fr) 2013-03-29 2019-11-27 Alexion Pharmaceuticals, Inc. Compositions et procédés pour augmenter la demi-vie sérique d'un agent thérapeutique ciblant c5 complémentaire
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
WO2015054298A1 (fr) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Méthodes pour empêcher la mort des cellules photoréceptrices ou réduire le nombre de cellules photoréceptrices mortes
AU2014370404A1 (en) 2013-12-24 2016-07-07 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
CN110724691A (zh) 2014-02-27 2020-01-24 阿勒根公司 补体因子Bb抗体
WO2017087391A1 (fr) 2015-11-17 2017-05-26 Bayer Healthcare, Llc Épitope d'anticorps monoclonaux humanisés optimisés dirigés contre la protéine c activée et leurs utilisations
CN110300520B (zh) 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
US11007254B2 (en) 2016-10-17 2021-05-18 Musc Foundation For Research Development Compositions and methods for treating central nervous system injury
JP7477457B2 (ja) * 2018-04-03 2024-05-01 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド Ｃ３結合薬及びその使用方法
US12110321B2 (en) * 2018-06-11 2024-10-08 Aarhus Universitet Single domain antibodies for complement regulation
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CA3214281A1 (fr) * 2021-03-19 2022-09-22 Elpis Biopharmaceuticals Anticorps specifiques a la lectine 15 de type ig se liant a l'acide sialique et leurs utilisations
WO2024108529A1 (fr) * 2022-11-25 2024-05-30 Linno Pharmaceuticals Inc. Protéine de liaison à la properdine et son utilisation
CR20240265A (es) 2021-12-22 2024-10-16 Boehringer Ingelheim Int Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
KR20230105972A (ko) 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
CN114874329A (zh) * 2022-05-19 2022-08-09 江苏大学 一种补体活化C1s酶荧光检测试剂盒及检测方法与应用
EP4590697A2 (fr) * 2022-09-20 2025-07-30 Visterra, Inc. Traitement de maladies et de troubles médiés par le complément avec des anticorps c3b

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP4764590B2 (ja) * 2000-04-29 2011-09-07 ユニバーシティー オブ アイオワ リサーチ ファウンデーション 黄班変性関連疾患の診断および治療
US7838165B2 (en) * 2004-07-02 2010-11-23 Kabushiki Kaisha Toshiba Carbon fiber synthesizing catalyst and method of making thereof
US20090004183A1 (en) * 2004-07-23 2009-01-01 Taylor Ronald P Compositions and Methods for Regulating the Alternative Pathway of Complement
MX2007006593A (es) * 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
CA2625681C (fr) * 2005-10-12 2016-08-02 Morphosys Ag Generation et profilage d'anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain
GB0613209D0 (en) * 2006-07-03 2006-08-09 Ucb Sa Methods
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof
RU2473563C2 (ru) * 2007-06-07 2013-01-27 Дженентек, Инк. АНТИТЕЛА ПРОТИВ C3b И СПОСОБЫ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ СВЯЗАННЫХ С КОМПЛЕМЕНТОМ НАРУШЕНИЙ
CL2008003241A1 (es) * 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares

Also Published As

Publication number Publication date
KR20120088551A (ko) 2012-08-08
AR076655A1 (es) 2011-06-29
CL2011002756A1 (es) 2012-03-23
UY32612A (es) 2010-12-31
TW201043638A (en) 2010-12-16
JP2012525829A (ja) 2012-10-25
PE20120899A1 (es) 2012-08-03
CA2760757A1 (fr) 2010-12-02
CO6440515A2 (es) 2012-05-15
EP2427491A2 (fr) 2012-03-14
WO2010136311A3 (fr) 2011-05-26
US20100291106A1 (en) 2010-11-18
CN102459334A (zh) 2012-05-16
SG175432A1 (en) 2011-12-29
TN2011000528A1 (en) 2013-05-24
IL216061A0 (en) 2012-01-31
AU2010252156A1 (en) 2011-11-10
EA201101593A1 (ru) 2012-06-29
MX2011011754A (es) 2011-11-29
WO2010136311A2 (fr) 2010-12-02
ECSP11011445A (es) 2012-01-31
ZA201107551B (en) 2012-07-25

Similar Documents

Publication Publication Date Title
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MA33757B1 (fr) Protéines de liaison à l'antigène de l'il-23 humaine
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
MA31502B1 (fr) Anticorps anti-notch 1 specifiques a nrr et ses procedes d'utilisation
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
UA106194C2 (ru) Диагностика и лечение рака с применением антитела к ereg
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
UA92505C2 (ru) Композиции на основе антитела против cd3
BR112012007365A2 (pt) proteínas de ligação à il-1
MA34527B1 (fr) Anticorps contre la metalloproteinase de matrice 9
MA40913A (fr) Conjugués anticorps-médicament
EA201100694A1 (ru) Антитело к cd38 человека и его применение
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
WO2008121615A3 (fr) Formulation d'anticorps
MA33256B1 (fr) Anticorps et immunoconjugués anti-fcrh5 et procédés d'utilisation
TW200642694A (en) Anti-M-CSF antibody compositions
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
MX2009006891A (es) Anticuerpos cd44.
MA34749B1 (fr) Anticorps anti-récepteur de la barrière hémato-encéphalique à faible affinité et leurs utilisations
EP2352523A4 (fr) Anticorps anti-cd19 améliorés
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
MA32725B1 (fr) Anticorps contre l'il 17 humaine et utilisations associees
EP2091975A4 (fr) Anticorps de la famille anti-egfr, anticorps de la famille anti-egfr bispécifiques et leurs procédés d'utilisation